Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

ORIGINAL ARTICLE
[View FULLTEXT] [Download PDF
 
Year : 2003  |  Volume : 49  |  Issue : 3  |  Page : 202-206  

Topiramate in the Treatment of Myoclonic-Astatic Epilepsy in Children: A Retrospective Hospital Audit

S Jayawant, SE Libretto 
 Department of Childhood Health, Paediatric Neurology Service, University Hospital of Wales, Cardiff, CF14 4XW and Janssen-Cilag Ltd., Saunderton, High Wycombe, Buckinghamshire HP14 4HJ, United Kindom

Correspondence Address:
S E Libretto
Janssen-Cilag Ltd., Saunderton, High Wycombe, Buckinghamshire HP14 4HJ
United Kindom

BACKGROUND: Myoclonic-Astatic Epilepsy (MAE) usually starts before five years of age and is associated with very frequent seizures and is highly resistant to treatment. AIM: To investigate the outcome of adjunctive topiramate (TPM) therapy in children with a diagnosis of MAE syndrome. Subjects AND METHODS: In an outpatient setting, case notes of 27 children who received TPM were retrieved and analysed. RESULTS: Records of 6 children with MAE, who were experiencing 2-8 atonic seizures daily before starting TPM were studied. Improvement was noted after addition of TPM (mean dose at steady-state 7.4±2.5mg/kg/day) to the regimen of 1-3 anti-epileptic drugs they were receiving concurrently. All but one child improved following the titration period: one had 50-80% improvement in the frequency of atonic seizures and three had over 80% improvement. However, one child who showed over 80% improvement and was free of atonic seizures, later developed increased frequency of other seizure types. In one child there was no significant improvement. Improvement has been sustained for over 6 months in three patients and over 4 months in one; three have continued TPM. TPM was stopped in three patients (reduction in seizure control/no improvement). CONCLUSIONS: This study supports the efficacy of TPM in controlling atonic seizures in MAE and indicates that it should be considered as an add-on drug in the management of this ‘difficult-to-treat’ epileptic syndrome.


How to cite this article:
Jayawant S, Libretto S E. Topiramate in the Treatment of Myoclonic-Astatic Epilepsy in Children: A Retrospective Hospital Audit .J Postgrad Med 2003;49:202-206


How to cite this URL:
Jayawant S, Libretto S E. Topiramate in the Treatment of Myoclonic-Astatic Epilepsy in Children: A Retrospective Hospital Audit . J Postgrad Med [serial online] 2003 [cited 2022 May 19 ];49:202-206
Available from: https://www.jpgmonline.com/article.asp?issn=0022-3859;year=2003;volume=49;issue=3;spage=202;epage=206;aulast=Jayawant;type=0


 
Thursday, May 19, 2022
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer